Search bioRxiv⌕ Search

bioRxiv · 10.1101/2020.11.30.403774

Dynamic modelling of the PI3K/mTOR signalling network uncovers biphasic dependence of mTORC1 activation on the mTORC2 subunit Sin1

Abstract

The PI3K/mTOR signalling network critically regulates a broad array of important biological processes, including cell growth, metabolism and autophagy. Dysregulation of PI3K/mTOR signalling is associated with a variety of human diseases, including cancer and metabolic disorders. The mechanistic target of rapamycin (mTOR) is a kinase that functions as a core catalytic subunit in two physically and functionally distinct complexes termed mTOR complex 1 (mTORC1) and mTORC2, which also share other common components such as mLTS8 (also known as G{beta}L) and DEPTOR. Despite being the subject of intensive research, a full picture of how mTORC1/2 assembly and activity are coordinated, and how they are functionally connected remain to be fully characterised. This is due primarily to the complex network wiring, featuring a growing number of intricate feedback loops and post-translational modifications, which require quantitative systems-level approaches to decipher. Here, we integrate predictive computational modelling, in vitro experiments and -omics data analysis to elucidate the dynamic and emergent features of the PI3K/mTOR network behavior. We construct new mechanistic models of the network that encapsulate novel critical mechanistic details, including mTORC1/2 coordination by mLTS8 (de)ubiquitination, and Akt-to-mTORC2 positive feedback loop. Model simulations subsequently confirmed by experimental validation revealed a previously unknown biphasic, threshold-gated dependence of mTORC1 activity on the key mTORC2 subunit Sin1, which is robust against cell-to-cell variation in protein expression. Furthermore, our results support the essential role of mLST8 in both mTORC1 and 2 activity, and suggest mLST8 could serve as a viable therapeutic target in breast cancer. Overall, our integrated analyses provide fresh systems-level insights into the dynamic behavior of PI3K/mTOR signalling and shed new light on the complexity of this important network. AUTHOR SUMMARYSignalling networks are the key information-processing machineries that underpin the ability of living cells to respond proportionately to extra- (and intra-) cellular cues. The PI3K/mTOR signalling network is one of the most important signalling networks in human cells that regulates cellular response to hormones such as insulin, yet our understanding of the network behaviour remains far from complete. Here, we employed a highly integrative approach that combines predictive mathematical modelling, biological experimentation, and data analysis to gain novel systems-level insights into PI3K/mTOR signalling. We constructed new mathematical models of this complex network incorporating important regulatory mechanisms. In contrary to commonly held views that mTORC2 lies upstream and is a positive regulator of mTORC1, we found that their relationship is highly nonlinear and dose dependent. This finding has major implications for mTORC2-directed anti-cancer strategies as depending on the cellular contexts, blocking mTORC2 may reduce or even enhance mTORC1 activation, the latter could inadvertently blunt the effect of mTORC2 blockade. Furthermore, our results demonstrate that mLST8 is required for the assembly and activity of both mTOR complexes, and suggest mLST8 is a viable therapeutic target in breast cancer, notably breast cancer.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Nguyen, L. K., Ghomlaghi, M., Shin, S., Yang, G., James, D. E.. 2020-11-30. Dynamic modelling of the PI3K/mTOR signalling network uncovers biphasic dependence of mTORC1 activation on the mTORC2 subunit Sin1. https://doi.org/10.1101/2020.11.30.403774

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

INFORME: coupling information-theoretic experimental design with nonlinear mixed-effects modeling for efficient observation scheduling

Mathematical models of treatment response can inform individualized therapy, but their calibration often requires longitudinal measurements that are costly, burdensome, and collected on fixed schedules. Such schedules may be inefficient, over-sampling patients whose response is already well characterized while delaying informative measurements for those whose model parameters remain uncertain. We present INFORME (INFORmation-theoretic design with Mixed Effects), a framework that combines Bayesian information-theoretic experimental design with nonlinear mixed-effects modeling to adaptively select each patients next measurement time. Population and response-subgroup parameter distributions learned from an existing cohort provide informative priors, allowing candidate measurement times to be ranked by their expected reduction in patient-specific parameter uncertainty. As observations accumulate, priors can be updated to reflect the response subgroup most consistent with the patients data. We evaluate INFORME in two radiotherapy datasets: 150 synthetic tumor volume trajectories from a hybrid cellular automaton model of prostate cancer spheroids (HD1) and longitudinal tumor volumes from 39 patients with head-and-neck cancer (HD2). In HD1, population priors allowed omission of both pretreatment scans, while adaptive scheduling reduced the protocol from nine scans to three or four, with the response group identified from a single post-treatment scan on day 27. In HD2, the adaptive schedule used three scans instead of six and improved prediction by delaying the first on-treatment scan from week 1 to week 2, avoiding transient dynamics that produced false-positive and false-negative response projections. Across both datasets, the adaptive schedules used a mean of 2.7 scans in stead of seven and advanced completion of the patient-specific prediction by a mean of 15.5 days (95% CI, 6.7-24.3) relative to the equidistant protocol, while treatment duration remained unchanged. INFORME therefore reduces measurement burden and accelerates patient-specific prediction by concentrating observations at times that are most informative for model calibration.

systems biology↗

Sobetirome, a thyroid hormone receptor beta agonist, is a potential therapeutic agent for pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with limited treatment options. Our group previously identified the antifibrotic potential of thyroid hormone, triiodothyronine (T3); however, clinical translation of thyroid hormone therapy is limited by its systemic adverse effects. In this study, we investigate whether sobetirome, a selective and well tolerated thyroid hormone receptor beta (THRB) agonist, offers antifibrotic benefits of thyroid hormone while minimizing systemic toxicity. Our study reveals that sobetirome, administered via intraperitoneal or inhalational routes, effectively mitigates bleomycin-induced pulmonary fibrosis in mice, with no evidence of toxicity. We identified that sobetirome restores mitochondrial homeostasis via activating the THRB-PPARGC1a axis. This protects alveolar type II epithelial cells from injury-induced apoptosis while selectively inducing apoptosis and metabolic reprogramming in apoptosis resistant IPF fibroblasts. Cell-specific deletion of Ppargc1a in either alveolar epithelial cells or fibroblasts abolishes sobetirome-mediated protection, establishing PPARGC1a as an essential mediator of therapeutic response. Importantly, sobetirome reverses fibrosis-associated transcriptional programs in human IPF lung tissue, reducing expression of key fibrosis-associated genes, including collagen I alpha 1 (COL1A1), collagen III alpha 1 (COL3A1), periostin (POSTN), cathepsin K (CTSK), and Chitinase 3 Like 1 (CHI3L1), while promoting extracellular matrix remodeling, epithelial restoration, and tissue homeostasis. Collectively, our findings identify THRB activation as a novel metabolic strategy for reversing pulmonary fibrosis. Across complementary in vitro, in vivo, and human ex vivo models, sobetirome restores mitochondrial function, modulates apoptotic pathways in pathogenic cells, and promotes fibrosis resolution, highlighting its potential as a lung-targeted therapeutic approach for IPF and other fibrotic lung diseases.

systems biology↗

Mechanistic modeling of bacterial translation initiation across growth conditions

Translation frequency in bacteria depends on how ribosomes, mRNAs, and initiation factors are allocated across growth conditions. Here, we developed a mechanistic ODE-based model of Escherichia coli translation that represents initiation, elongation, termination, and coupled auxiliary processes. Growth-dependent abundances were derived from physiological relationships and reprocessed omics data, and simulated outputs were compared with translation-frequency and active-ribosome references. The model predicts a continuous shift from complex-formation-limited toward ribosome-limited behavior as growth increases. This shift is characterized by a decline in free-ribosome abundance, whereas initiation-factor pools remain largely unbound and do not become depleted in parallel. Together with the implemented IF-dependent kinetic term, this preserved availability provides a model-internal route through which productive initiation can be maintained despite increasing ribosome utilization. Consistently, transcript-wide ribosome loading remains below its theoretical maximum, while COG-level simulations reveal distinct sector-specific translation-frequency trajectories. The study therefore provides a resource-allocation framework for interpreting how mRNA--ribosome interactions shape bacterial translation across growth conditions.

systems biology↗